# A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age

> **NCT07222670** · PHASE2 · RECRUITING · sponsor: **ENA Respiratory Pty Ltd** · enrollment: 1100 (estimated)

## Conditions studied

- Viral Respiratory Infection
- Viral Respiratory Illnesses

## Interventions

- **DRUG:** INNA-051
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07222670
- **Lead sponsor:** ENA Respiratory Pty Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-04
- **Primary completion:** 2027-02-09
- **Final completion:** 2027-02-09
- **Target enrollment:** 1100 (ESTIMATED)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07222670

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07222670, "A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT07222670. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*